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develop while clarity on methods to evaluate the cognitive impact of this technol-
ogy have lagged. The steps we present provide a standardized system for ensuring 
that ePROs measure what is intended and the risk to research data is minimized.
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Objectives: Although missing and incomplete responses in ePROs can be mini-
mized through risk assessment and mitigation plans, missing data can have varying 
implications on clinical trials. This conceptual paper assesses the impact of missing 
ePRO data to the trial, taking into account the phase of the trial and intended use 
of the data. MethOds: Common uses for data gathered via ePRO instruments and 
diaries are reviewed. An assessment of the impact of different levels of missing 
data and associated risks with analyzing data is also performed. Results: Data 
gathered via ePRO are frequently used to support primary/secondary trial endpoints. 
They are also commonly used for exploratory purposes, allowing sponsors to gather 
preliminary information to guide the planning of future trials. Types of data col-
lected may include study medication usage for study drug reconciliation reasons, 
symptom presence or severity to determine eligibility for trial participation, and 
responses over time to indicate improvement or worsening of the symptom/disease. 
Each data use is assessed for risks to the analyzability of the data associated with 
different levels of missing data. For example, in projects with ePRO responses used 
to support primary/secondary endpoints overall project risk is low when compliance 
rates are high (e.g. 90-100%). As compliance rates drop to < 80%, bias introduced in 
the results increases, quality of the data decreases, and risks that the data may 
not be able to be used in the analysis rises. Impacts could include a need to recruit 
additional patients or that the trial may need to be re-run. cOnclusiOns: Impacts 
of missing data on clinical trial analysis vary depending on the intended use of the 
data. It is important to understand the impact of missing data to the project so that 
an appropriate plan can be decided upon and included in the protocol.
PRM136
Methodological and oPeRational consideRations in conducting 
RetRosPective Medical chaRt Review studies in hosPitals and 
Medical centeRs in eMeRging MaRkets
Solem C.T.1, Macahilig C.P.2, Katyal M.2, Li J.Z.3, Haider S.4, Raghubir N.4, Stephens J.M.1
1Pharmerit International, Bethesda, MD, USA, 2Medical Data Analytics, Parsippany, NJ, USA, 
3Pfizer, Inc., San Diego, CA, USA, 4Pfizer, Groton, CT, USA
Objectives: Retrospective medical chart reviews are an increasingly valuable 
source of data for clinical, treatment patterns, and outcomes research, particularly 
in emerging markets where availability of databases for secondary analysis is lim-
ited. This abstract aims to describe methodological and operational considerations 
that sponsors and researchers should be aware of prior to and during the undertak-
ing of chart review studies in these markets. MethOds: Key considerations for 
executing chart review studies in hospitals and major medical centers from study 
conception through the completion and quality review of data collection were iden-
tified and summarized. Results: After identification of research objectives and 
target countries/markets for research, thoughtful consideration of site selection 
(single or multi-site/country, local investigator interest and availability), data avail-
ability (nature, comprehensiveness, and quality of existing medical records), and 
patient selection (sampling design, specificity of inclusion/exclusion criteria) form 
the basis for implementing a successful chart review. Study design steps may be 
taken to optimize performance, for example: careful consideration of how inclusion/ 
exclusion criteria will impact patient recruitment given the rarity of the study condi-
tion (data on this may be limited); assessing feasibility of data collection instrument 
completion via piloting and prior local experience; standardization of terms and 
definitions to ensure cross-site comparability. Additional operational considerations 
include meeting varied requirements for obtaining national/state and local ethics 
approval in multi-country studies, use of electronic data capture given variation in 
information technology infrastructure across study sites, and impact of workday/
cultural traditions on recruitment/ timelines. cOnclusiOns: To maximize the 
opportunity for successful medical chart review studies in emerging markets, review 
and assessment of operational feasibilities in the target research areas, appropriate 
tailoring of study objectives, engagement of local investigators and site staff, and 
continuous oversight of data collection and quality control processes are essential.
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It is often the case that cost-effectiveness models need to consider the sequence 
of treatments in a treatment algorithm. Since traditional state transition Markov 
models have an inherent memoryless property, time dependency in time to event 
analysis cannot be incorporated in this modelling framework. This has been used 
as a rationale for moving to individual level simulation models to handle treatment 
sequences. However, individual simulation models increase the computational bur-
den of a model, particularly when it comes to undertaking real-time probabilistic 
sensitivity analysis to characterize uncertainty. Therefore, adifferent approach to 
modeling treatment sequencing should be examined. In this paper, we discuss a 
novel approach to analyzing sequencing models that allow time dependency in the 
time to event analysis within a cohort model framework,thus avoiding the disad-
vantages of resorting to individual simulation. Typically parametric survival models 
can be used to characterize time to event. This may be time to overall survival or 
time to progression in cancer modelling, or time to treatment failure / treatment 
switching in oncology. We illustrate the approach using parametricWeibull models, 
although in principle any parametric survival model could be used. We show how 
sources may be integrated in order implement prospective observational research 
studies that answer complex research questions.
ReseaRch on Methods – conceptual Papers
PRM132
what aRe the Roles of health econoMic Models in PRoduct 
develoPMent?
Wu E., Davies G.M., Koglin J., Cook J.
Merck, North Wales, PA, USA
Objectives: Health economic models are widely used for drug evaluation during 
the post-approval and reimbursement process. However, similar models can also 
be used to inform objectives, decisions and designs earlier in the drug develop-
ment process with the idea to optimize the potential future value to payers. This 
project assesses how an economic heart failure (HF) model can facilitate the deci-
sion making process during the early stages of drug development. MethOds: A 
discrete event simulation is developed to track the events associated with disease 
progression of HF patients over 5 years. Patients are initially categorized into one 
of three health states based on their HF status: in-hospital, 30 days post-discharge 
and > 30 days post-discharge. To capture movement in the model, the time to hos-
pital discharge, re-hospitalization and death are generated based on each patient’s 
current health state and the event rates taken from available literature. The model 
is used to identify baseline levels of risk, a range of potential prices or the required 
drug efficacy that the drug candidate needs to meet in order to be cost-effective 
compared to standard care. Results: By way of illustration, we considered a patient 
with baseline mortality risk of 0.1% and a 0.2% readmission rate per day. If treatment 
costing $1 /day is provided to patients outside of hospital, a mortality reduction of at 
least 12% is needed to meet a $25,000/QALY threshold. For a higher risk population, 
the treatment can remain cost-effective at either a higher price or lower clinical 
efficacy. cOnclusiOns: This study demonstrates that health economic models 
are useful to determine the acceptable ranges of baseline risk, efficacy, and price to 
assess the potential value of future drug candidates.
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Objectives: To explore the appropriate use of surrogates within an economic 
modeling framework, compared to the statistical approaches of validating sur-
rogates. MethOds: We reviewed the statistical literature on validating surrogate 
endpoints. Published statistical approached to validating surrogate endpoints 
include those described by Prentice and Buyse. We explore the use of these sta-
tistical approaches to validation in the context of health economic models where 
surrogates are used (a) predict final outcomes, and (b) as endpoints for stopping 
rules and patient access schemes. Results: Given regulatory trials powered on 
surrogate endpoints, economic modeling often requires the use of surrogate end-
points to estimate the impact of treatment on final health outcomes of interest to 
reimbursement agencies. This requirement occurs even when there is no statisti-
cal validation of the surrogacy relationship, or when the surrogate fails a formal 
statistical validation. As a consequence we argue that the appropriate focus for 
economic modeling is on the appropriate propagation of uncertainty in the esti-
mates of the effect of the surrogate on final health outcome and the avoidance of 
bias due to multiple testing rather than the formal testing of validity. This includes 
the use of stopping rules that are designed to improve cost-effectiveness estimates 
for patient access. cOnclusiOns: The approach to surrogacy in reimbursement 
is necessarily different to that in a regulatory environment. We outline a general 
estimation approach based on appropriately characterizing uncertainty in the sur-
rogacy relationship rather than the formal statistical testing of surrogate validity 
as the appropriate focus of reimbursement models.
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AiMs: Use of electronically administered outcome measures is increasing in clinical 
trial data collection. The 2009 ISPOR ePRO Task Force Report recommends cogni-
tive assessment as sufficient evidence of equivalence when only minor changes 
have been made to the measure. No consensus exists, however, for how cognitive 
assessment results should be evaluated to determine if equivalence has been estab-
lished. MethOds: Existing literature around equivalence assessment for PROs was 
combined with firsthand experience in conducting over 500 cognitive interviews 
aimed at assessing paper and electronic equivalence of 55 different PRO instru-
ments. Using these two resources, we developed suggested criteria to cognitively 
assess equivalence between the two modes, and present a practical process for 
meeting these criteria. Results: The criteria for determining equivalence between 
paper and ePRO formats should focus primarily on whether or not the ePRO is likely 
to produce data substantially different if administered via one method versus the 
other. To determine whether such a risk to ePRO data exists, we propose a three-
step process for interpreting cognitive interview responses. 1) Determine whether a 
patient perceives a cognitive difference between paper PRO and ePRO, and whether 
that difference represents a variation in the understanding of the item or simply a 
recognition of different appearance; 2) Determine whether any difference in patient 
understanding has a meaningful impact on their response to the item, and 3) deter-
mine whether or not that difference presents a significant risk to the data that 
justifies modification of the ePRO. cOnclusiOns: In the years since the ISPOR ePRO 
Task Force issued their recommendations, data capture technology has continued to 
